Bank of America has revised its price target for Amphastar Pharmaceuticals (AMPH, Financial), reducing it from $36 to $31 while maintaining a Neutral rating on the company's stock. The adjustment comes as part of the firm's early analysis of first-quarter earnings per share updates in the commercial-stage biopharma sector.
According to Bank of America, the first quarter often presents challenges due to various seasonal factors, which can make financial results appear less consistent. The firm suggests that this pattern typically leads to a broader acceptance of initial performance reports, with a focus on anticipated growth in the latter part of the year. Additionally, there is a possibility that Q1 outcomes could be overshadowed by broader concerns related to pharmaceutical tariffs.
As investors consider Amphastar's (AMPH, Financial) stock performance, they are prompted to look beyond the immediate results to future expectations that may hold more significance for the company's growth trajectory later in the year.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 4 analysts, the average target price for Amphastar Pharmaceuticals Inc (AMPH, Financial) is $36.50 with a high estimate of $40.00 and a low estimate of $32.00. The average target implies an upside of 57.53% from the current price of $23.17. More detailed estimate data can be found on the Amphastar Pharmaceuticals Inc (AMPH) Forecast page.
Based on the consensus recommendation from 6 brokerage firms, Amphastar Pharmaceuticals Inc's (AMPH, Financial) average brokerage recommendation is currently 2.3, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Amphastar Pharmaceuticals Inc (AMPH, Financial) in one year is $52.93, suggesting a upside of 128.44% from the current price of $23.17. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Amphastar Pharmaceuticals Inc (AMPH) Summary page.
